loading
전일 마감가:
$0.588
열려 있는:
$0.571
하루 거래량:
98,282
Relative Volume:
0.21
시가총액:
$24.28M
수익:
$1.38M
순이익/손실:
$-179.05M
주가수익비율:
-0.0809
EPS:
-7.11
순현금흐름:
$-155.03M
1주 성능:
+10.01%
1개월 성능:
+4.24%
6개월 성능:
-71.52%
1년 성능:
-85.32%
1일 변동 폭
Value
$0.565
$0.5801
1주일 범위
Value
$0.511
$0.6114
52주 변동 폭
Value
$0.50
$4.17

바이오엑셀 테라퓨틱스 Stock (BTAI) Company Profile

Name
명칭
Bioxcel Therapeutics Inc
Name
전화
203-643-8060
Name
주소
555 LONG WHARF DRIVE, NEW HAVEN, CT
Name
직원
74
Name
트위터
@bioxcel_tx
Name
다음 수익 날짜
2024-11-12
Name
최신 SEC 제출 서류
Name
BTAI's Discussions on Twitter

BTAI을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
BTAI 0.5701 24.28M 1.38M -179.05M -155.03M -7.11
VRTX 449.11 115.43B 10.63B -479.80M -1.35B 13.33
REGN 746.63 82.04B 13.85B 4.65B 3.32B 35.06
ARGX 597.08 35.30B 1.86B -40.29M -1.28B -4.16
ALNY 246.44 32.04B 2.09B -332.26M 16.06M -4.14
BNTX 108.09 24.89B 3.30B -501.07M 1.03B 11.54

바이오엑셀 테라퓨틱스 Stock (BTAI) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2023-08-15 다운그레이드 Mizuho Buy → Neutral
2023-07-17 다운그레이드 Guggenheim Buy → Neutral
2023-03-10 다운그레이드 Jefferies Buy → Hold
2022-12-01 업그레이드 Goldman Sell → Neutral
2022-07-07 개시 Mizuho Buy
2022-04-06 재확인 BofA Securities Buy
2021-11-15 다운그레이드 Goldman Neutral → Sell
2021-04-09 개시 Berenberg Buy
2021-02-01 개시 UBS Buy
2020-10-30 개시 Goldman Buy
2020-09-02 개시 Jefferies Buy
2020-08-17 재확인 H.C. Wainwright Buy
2020-07-08 재확인 H.C. Wainwright Buy
2020-06-04 개시 Guggenheim Buy
2020-04-01 개시 BofA/Merrill Buy
2020-02-26 재확인 H.C. Wainwright Buy
2020-01-08 재확인 H.C. Wainwright Buy
2019-11-12 개시 SunTrust Buy
모두보기

바이오엑셀 테라퓨틱스 주식(BTAI)의 최신 뉴스

pulisher
Nov 18, 2024

BioXcel Therapeutics, Inc. (BTAI) Reports Q3 Loss, Lags Revenue Estimates - MSN

Nov 18, 2024
pulisher
Nov 15, 2024

BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Q3 2024 Earnings Call Transcript - Insider Monkey

Nov 15, 2024
pulisher
Nov 15, 2024

BioXcel Therapeutics Inc (BTAI) Q3 2024 Earnings Call Highlights: Strategic Trials and Financial Adjustments - GuruFocus.com

Nov 15, 2024
pulisher
Nov 15, 2024

BioXcel Therapeutics Inc (BTAI) Q3 2024 Earnings Call Highlights: Strategic Trials and ... By GuruFocus - Investing.com Canada

Nov 15, 2024
pulisher
Nov 15, 2024

BioXcel Therapeutics Inc (BTAI) Q3 2024 Earnings Call Highlights: Strategic Trials and ... - Yahoo Finance

Nov 15, 2024
pulisher
Nov 15, 2024

BioXcel Therapeutics Inc. (BTAI) Quarterly 10-Q Report - Quartz

Nov 15, 2024
pulisher
Nov 14, 2024

BioXcel Therapeutics stock hits 52-week low at $0.5 By Investing.com - Investing.com Australia

Nov 14, 2024
pulisher
Nov 14, 2024

BioXcel Therapeutics Reports Q3 2024 Financial Results - TipRanks

Nov 14, 2024
pulisher
Nov 14, 2024

BioXcel Therapeutics stock hits 52-week low at $0.5 - Investing.com India

Nov 14, 2024
pulisher
Nov 14, 2024

Earnings call: BioXcel Therapeutics reports Q3 2024 financials - Investing.com

Nov 14, 2024
pulisher
Nov 14, 2024

BioXcel Therapeutics earnings beat by $0.19, revenue fell short of estimates - Investing.com Canada

Nov 14, 2024
pulisher
Nov 14, 2024

BioXcel Therapeutics Inc Reports Q3 2024 Earnings: Net Revenue a - GuruFocus.com

Nov 14, 2024
pulisher
Nov 14, 2024

BioXcel Therapeutics Reports Third Quarter 2024 Financial Results - GlobeNewswire

Nov 14, 2024
pulisher
Nov 14, 2024

Critical Survey: Emergent BioSolutions (NYSE:EBS) vs. BioXcel Therapeutics (NASDAQ:BTAI) - Defense World

Nov 14, 2024
pulisher
Nov 13, 2024

What To Expect From BioXcel Therapeutics Inc (BTAI) Q3 2024 Earnings - GuruFocus.com

Nov 13, 2024
pulisher
Nov 13, 2024

BioXcel Therapeutics (BTAI) Set to Announce Earnings on Thursday - Defense World

Nov 13, 2024
pulisher
Nov 12, 2024

BioXcel advances trials for acute agitation treatments - Investing.com India

Nov 12, 2024
pulisher
Nov 12, 2024

BioXcel advances trials for acute agitation treatments By Investing.com - Investing.com UK

Nov 12, 2024
pulisher
Nov 12, 2024

BioXcel Therapeutics Advances Pivotal Phase 3 Trials of BXCL501 for Acute Treatment of Agitation Associated with Bipolar Disorders, Schizophrenia, and Alzheimer's Dementia - The Manila Times

Nov 12, 2024
pulisher
Nov 12, 2024

BioXcel Therapeutics Advances Pivotal Phase 3 Trials of - GlobeNewswire

Nov 12, 2024
pulisher
Nov 12, 2024

BioXcel's Phase 3 Breakthrough: First Patient Enrolled in Critical Agitation Treatment Trial | BTAI Stock News - StockTitan

Nov 12, 2024
pulisher
Nov 08, 2024

BioXcel Therapeutics to Report Third Quarter 2024 Financial Results on November 14, 2024 - GlobeNewswire

Nov 08, 2024
pulisher
Nov 05, 2024

Will BioXcel Therapeutics, Inc. (BTAI) Report Negative Q3 Earnings? What You Should Know - MSN

Nov 05, 2024
pulisher
Oct 30, 2024

ROSEN, TRUSTED AND TOP RANKED INVESTOR COUNSEL, Encourages BioXcel Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class ActionBTAI - Marketscreener.com

Oct 30, 2024
pulisher
Oct 29, 2024

BioXcel Therapeutics to Present at ThinkEquity Conference - The Manila Times

Oct 29, 2024
pulisher
Oct 28, 2024

Pre-market Movers: EVOK, HCTI, GLUE, MNPR... - RTTNews

Oct 28, 2024
pulisher
Oct 23, 2024

BioXcel Therapeutics (NASDAQ:BTAI) PT Lowered to $5.00 - Defense World

Oct 23, 2024
pulisher
Oct 19, 2024

BioXcel announces defense grant to UNC to fund study for treating acute stress disorder - MSN

Oct 19, 2024
pulisher
Oct 15, 2024

BioXcel Therapeutics partners with UNC for ASD trial By Investing.com - Investing.com Australia

Oct 15, 2024
pulisher
Oct 15, 2024

BioXcel Therapeutics partners with UNC for ASD trial - Investing.com India

Oct 15, 2024
pulisher
Oct 15, 2024

BioXcel Therapeutics Announces U.S. Department of Defense - GlobeNewswire

Oct 15, 2024
pulisher
Oct 15, 2024

BioXcel Therapeutics Announces U.S. Department of Defense Grant to University of North Carolina to Fund Study of BXCL501 (Sublingual Dexmedetomidine) for Treating Acute Stress Disorder - StockTitan

Oct 15, 2024
pulisher
Oct 10, 2024

BioXcel Therapeutics reports executive transition - Investing.com India

Oct 10, 2024
pulisher
Oct 09, 2024

BioXcel Therapeutics reports executive transition By Investing.com - Investing.com Australia

Oct 09, 2024
pulisher
Oct 09, 2024

Investing in BioXcel Therapeutics Inc (BTAI) Is Getting More Attractive - Knox Daily

Oct 09, 2024
pulisher
Oct 04, 2024

BioXcel Therapeutics executive sells shares worth over $3,000 By Investing.com - Investing.com Australia

Oct 04, 2024
pulisher
Oct 04, 2024

BioXcel Therapeutics CSO sells shares worth $3,946 By Investing.com - Investing.com South Africa

Oct 04, 2024
pulisher
Oct 04, 2024

BioXcel Therapeutics executive sells shares worth $3,449 By Investing.com - Investing.com Australia

Oct 04, 2024
pulisher
Oct 04, 2024

BioXcel therapeutics officer Javier Rodriguez sells shares worth $3,774 By Investing.com - Investing.com South Africa

Oct 04, 2024
pulisher
Oct 03, 2024

Bioxcel therapeutics CFO sells shares worth $3,946 By Investing.com - Investing.com Canada

Oct 03, 2024
pulisher
Oct 03, 2024

Bioxcel therapeutics CFO sells shares worth $3,946 - Investing.com

Oct 03, 2024
pulisher
Oct 03, 2024

BioXcel Therapeutics executive sells shares worth over $3,000 - Investing.com

Oct 03, 2024
pulisher
Oct 03, 2024

BioXcel Therapeutics CSO sells shares worth $3,946 - Investing.com India

Oct 03, 2024
pulisher
Oct 03, 2024

BioXcel therapeutics officer Javier Rodriguez sells shares worth $3,774 - Investing.com

Oct 03, 2024
pulisher
Oct 03, 2024

BioXcel Therapeutics executive sells shares worth $3,449 - Investing.com

Oct 03, 2024

바이오엑셀 테라퓨틱스 (BTAI) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading
$18.98
price up icon 1.80%
$70.68
price down icon 0.42%
$38.38
price up icon 3.49%
$369.83
price up icon 1.48%
$196.58
price up icon 0.88%
$102.64
price up icon 0.27%
자본화:     |  볼륨(24시간):